SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

"The counterintuitive thesis driving SELLAS bulls is that the trial is taking longer than expected to reach that 80th event, and that is a feature, not a bug. Only 12 deaths occurred among 66 at-risk patients during the trial observation window, suggesting a lower-than-expected mortality rate versus the historical baseline for this patient population."

"Social sentiment has been firmly 'Very Bullish,' with scores ranging from 78 to 88 across r/stocks and r/wallstreetbets over the past 48 hours. The most detailed public case came from a r/wallstreetbets due diligence post by user Confident-Web-7118, who claims to hold 805,000 shares and spent over 1,000 hours on the analysis."

SELLAS Life Sciences Group has seen a 346% increase in shares over the past year, despite a recent 13.4% pullback. The Phase 3 REGAL trial for its WT1-targeting cancer vaccine in AML patients requires 80 patient deaths for final analysis, with 72 recorded as of late December 2025. A lower-than-expected mortality rate is viewed positively by investors. Social sentiment on Reddit has been very bullish, with detailed analyses supporting the potential success of the trial and the vaccine's efficacy.

Read at 24/7 Wall St.